KRAS/NRAS/BRAF Mutations Detection Kit
PCR
Real-time PCR Assays
1%
1%
Sensitivity
100%
100%
Accuracy
Features
Selectable
- Pre-loaded formats are available.
1
- Pre-loaded formats are available.
Universal
- Compatible with tissue samples.
2
- Compatible with tissue samples.
Precise
- Top sensitivity of 1% mutant allele.
3
- Top sensitivity of 1% mutant allele.
Easy
- One-step procedure, results in 90 mins.
4
- One-step procedure, results in 90 mins.
Reliable
- Internal and external controls included.
5
- Internal and external controls included.
Product Description

KRAS/NRAS/BRAF Mutations Detection Kit

KRAS, NRAS and BRAF gene are the key molecules in the downstream signaling pathway of epidermal growth factor receptor (EGFR), which transduce signals from membrane-bound receptors via multiple downstream effector pathways and thereby affect fundamental cellular processes, including proliferation, apoptosis, and differentiation. In total, activating KRAS and NRAS mutations occur in 20~50% and 1~6% of colorectal cancers respectively, mainly in exons 2, 3 or 4. And the most common BRAF mutations are V600 mutations in exon 15, which occur in 8〜15% of colorectal cancers.

Studies have shown the mutation status of the KRAS, NRAS and BRAF gene is relevant to the primary drug resistance of colorectal cancers treated with anti-EGFR monoclonal antibodies. Patients with wild-type KRAS and NRAS gene could benefit from Erbitux (Cetuximab) or Vectibix (Panitumumab), whereas, the patients with mutant KRAS or NRAS gene show poor response to this treatment. And BRAF gene mutations predict poor prognosis of such treatments. As a result, KRAS, NRAS and BRAF mutations detection supplies evidence for targeted clinical therapy of tumor patients, which decreases cost and time of treatment.

Intended Use 

The AmoyDx® KRAS/NRAS/BRAF Mutations Detection Kit is a real-time PCR assay for qualitative detection of 17 KRAS mutations (exons 2, 3 and 4), 13 NRAS mutations (exons 2, 3 and 4) and BRAFV600E mutation (exon 15) in human genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue. The kit is intended to assess KRAS/NRAS/BRAF mutation status in colorectal cancer patient.

The kit is for in vitro diagnostic use, and intended to be used by trained professionals in a laboratory environment.

Download
Testing Procedure
Compatible Sample Types:FFPE Samples
Compatible Real-time PCR Instrument
ABI 7500
LightCycler 480
SLAN-96S
Stratagene Mx3000P™
Other Info.

To order, please contact sales@amoydx.com.

 Product Name

Type

Size (test/kit)

 Storage

KRAS/NRAS/BRAF Mutations Detection Kit

Pre-loaded

6

-20℃


Publications
1. Guo, Tian‐An, et al. "Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single‐center retrospective study of 1,834 Chinese patients with Stage I–IV colorectal cancer." International journal of cancer 145.6 (2019): 1625-1634.
2. Huang, Fengbo, et al. "Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma: A Clinicopathologic Study of Five Cases and a Literature Review." American journal of clinical pathology 152.5 (2019): 582-589.

Certificate
BACK
Inquiry
Inquiry
* Required information
Manage your account info
Change your password